bluebird bio stock slides for second day on buyout news
bluebird bio stock slides for second day on buyout news
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker - CNBC
bluebird bio announces take-private deal with Carlyle and SK Capital
Dow Jones Newswires: Bluebird Bio stock rises 62%, FDA committee supports treatments
39.06MUSD
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US09609G2093
CUSIP
09609G100
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
0.32
Book Value
-0.60
Dividend Share
-
Dividend Yield
-
Earnings Share
-36
Wall Street Target Price
14.50
EPS Estimate Current Year
-27.67
EPS Estimate Next Year
-9.70
EPS Estimate Current Quarter
-0.35
EPS Estimate Next Quarter
-0.22
Most Recent Quarter
-
Revenue TTM
53,120,000
Gross Profit TTM
-25,663,000
EBITDA
-262,272,000
Profit Margin
0.00%
Return On Assets TTM
-36.91%
Return On Equity TTM
-270.20%
Revenue Per Share TTM
6.077
Qtly Revenue Growth YOY
-14.40%
Diluted Eps TTM
-36
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
0
Price Sales TTM
0.7262
Price Book MRQ
0.726
Enterprise Value Revenue
6
Enterprise Value EBITDA
-1
98.50
6.14%244.99
2.61%591.45
1.76%100.00
1.71%249.00
1.34%494.74
1.33%78.89
0.66%184.83
0.00%689.50
-3.89%155.48
-0.30%